Meropenem Xiromed

Meropenem, the active ingredient in Meropenem Xiromed, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections in hospitalized patients, including those caused by multidrug‑resistant organisms.

GNH USA supplies Meropenem Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious infections caused by susceptible bacteria. - Complicated intra‑abdominal infection: provides coverage against Gram‑negative, Gram‑positive and anaerobic pathogens. - Complicated urinary tract infection: eradicates resistant Enterobacteriaceae and Pseudomonas species. - Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: achieves high lung tissue concentrations. - Bacterial sepsis and meningitis: penetrates the bloodstream and cerebrospinal fluid to treat systemic infections.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis during infusion. - Diarrhea: may be self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema. - Infusion site phlebitis: local irritation at IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Anaphylaxis: acute hypersensitivity reaction. - Renal toxicity: elevated creatinine levels. - Hepatic enzyme elevation: transient transaminase increase. - Severe neutropenia: marked reduction in white blood cells.

Meropenem should be used with consideration of patient‑specific factors. - Renal function: adjust dose in patients with impaired renal function. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor patients with a history of CNS disorders. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concomitant valproic acid: monitor serum valproate levels as they may decrease. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medicines; clinical monitoring is advised.

Major Interactions (Avoid): - Valproic acid: meropenem can significantly reduce serum valproate concentrations. - Probenecid: may increase meropenem plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: combined use may heighten nephrotoxicity. - Aminoglycosides: additive renal toxicity potential. - Warfarin: meropenem may potentiate anticoagulant effect, requiring INR monitoring.